Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 410 $ 108
Operating expenses:    
Research and development (related party of $0 and $97) 1,762 977
General and administrative (related parties of $393 and $321) 5,572 2,986
Total operating expenses 7,334 3,963
Operating loss (6,924) (3,855)
Other income (expense):    
Interest expense - related party (614) (620)
Interest income 4 4
Royalty income 0 7
Total other income (expense) (610) (609)
Consolidated net loss (7,534) (4,464)
Net loss attributable to noncontrolling interest 1 1
Net loss attributable to iBio, Inc. (7,533) (4,463)
Preferred stock dividends (66) (66)
Net loss available to iBio, Inc. (7,599) (4,529)
Comprehensive loss:    
Consolidated net loss (7,534) (4,464)
Other comprehensive loss - unrealized loss on securities (7) 0
Other comprehensive loss - foreign currency translation adjustments 0 (1)
Comprehensive loss $ (7,541) $ (4,465)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.05) $ (0.21)
Weighted-average common shares outstanding - basic and diluted 162,442 21,923